Search

To study effect of symbicort turbuhaler (ST) combined with montelukast on pulmonary function and serum cytokine levels in patients with acute stage of bronchial asthma(ASBA). 86 patients with ASBA who were treated in our hospital from February 2015 to August 2017 were selected as research subjects. The patients were divided into the observation group (n=43) and the control group (n=43) according to the random number table method. The control group was treated with ST, and the observation group was treated with montelukast on the basis of the control group, two groups were treated for 3 months. The lung function, cytokine levels, cough score, St. George's respiratory disease questionnaire (SGRQ) before treatment and 3 months after treatment and drug safety were compared between the two groups. After treatment, the levels of forced expiratory volume (FEV1), forced vital capacity (FVC) and FEV1/FVC in the two groups were increased significantly compared with those before treatment, and the observation group was higher than that of the control group (P<0.05). After treatment, the levels of interleukin-4 (IL-4), interleukin-5 (IL-5), interferon-酌 (INF-酌) and tumor necrosis factor-琢 (TNF-琢) in the two groups were all lower than those before treatment, and the observation group was lower than that in the control group (P<0.05). After treatment, the scores of cough in two groups were significantly higher than before treatment, and the observation group was significantly higher than the control group(P<0.05). After treatment, the scores of SGRQ in two groups were significantly lower than before treatment, and the observation group was significantly lower than the control group(P<0.05). The total incidence of adverse reactions in the observation group was 20.93%, and there was no statistical difference compared with 16.28% of the control group (P>0.05). ST combined with montelukast can effectively improve the symptoms of the ASBA patients, alleviate the inflammatory reaction of the body and improve the pulmonary function and quality of life of the patients at the same time. [ABSTRACT FROM AUTHOR]

Bronchial asthma is a worldwide chronic airway inflammatory respiratory disease, in recent years, with the increase of air pollution and the increasing number of smokers, the incidence of the disease has increased year by year, which has attracted more and more people’s attention. Bronchial asthma is caused by a variety of factors such as genetic factors, biological factors, psychological factors and other factors, with the deepening of research, great progress has been made in the study of the effect of psychological factors on bronchial asthma, there are obvious personality characteristics and emotional disorders in the patients with bronchial asthma, and the patient’s personality characteristics and emotional disorders will have a certain impact on the patient’s condition and quality of life. In view of this, this article gives a brief account of the personality characteristics, emotional characteristics and its influence on the disease for the clinical reference. [ABSTRACT FROM AUTHOR]